Copyright Reports & Markets. All rights reserved.

Global Becker Muscular Dystrophy Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Becker Muscular Dystrophy Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Becker Muscular Dystrophy Drug Market Size Growth Rate by Product
      • 1.4.2 Givinostat
      • 1.4.3 Ataluren
      • 1.4.4 Epicatechin
      • 1.4.5 ARM-210
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Becker Muscular Dystrophy Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Becker Muscular Dystrophy Drug Market Size
      • 2.1.1 Global Becker Muscular Dystrophy Drug Revenue 2014-2025
      • 2.1.2 Global Becker Muscular Dystrophy Drug Sales 2014-2025
    • 2.2 Becker Muscular Dystrophy Drug Growth Rate by Regions
      • 2.2.1 Global Becker Muscular Dystrophy Drug Sales by Regions
      • 2.2.2 Global Becker Muscular Dystrophy Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Becker Muscular Dystrophy Drug Sales by Manufacturers
      • 3.1.1 Becker Muscular Dystrophy Drug Sales by Manufacturers
      • 3.1.2 Becker Muscular Dystrophy Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Becker Muscular Dystrophy Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Becker Muscular Dystrophy Drug Revenue by Manufacturers
      • 3.2.1 Becker Muscular Dystrophy Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Becker Muscular Dystrophy Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Becker Muscular Dystrophy Drug Price by Manufacturers
    • 3.4 Becker Muscular Dystrophy Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Becker Muscular Dystrophy Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Becker Muscular Dystrophy Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Becker Muscular Dystrophy Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Becker Muscular Dystrophy Drug Sales by Product
    • 4.2 Global Becker Muscular Dystrophy Drug Revenue by Product
    • 4.3 Becker Muscular Dystrophy Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Becker Muscular Dystrophy Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Becker Muscular Dystrophy Drug by Countries
      • 6.1.1 North America Becker Muscular Dystrophy Drug Sales by Countries
      • 6.1.2 North America Becker Muscular Dystrophy Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Becker Muscular Dystrophy Drug by Product
    • 6.3 North America Becker Muscular Dystrophy Drug by End User

    7 Europe

    • 7.1 Europe Becker Muscular Dystrophy Drug by Countries
      • 7.1.1 Europe Becker Muscular Dystrophy Drug Sales by Countries
      • 7.1.2 Europe Becker Muscular Dystrophy Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Becker Muscular Dystrophy Drug by Product
    • 7.3 Europe Becker Muscular Dystrophy Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Becker Muscular Dystrophy Drug by Countries
      • 8.1.1 Asia Pacific Becker Muscular Dystrophy Drug Sales by Countries
      • 8.1.2 Asia Pacific Becker Muscular Dystrophy Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Becker Muscular Dystrophy Drug by Product
    • 8.3 Asia Pacific Becker Muscular Dystrophy Drug by End User

    9 Central & South America

    • 9.1 Central & South America Becker Muscular Dystrophy Drug by Countries
      • 9.1.1 Central & South America Becker Muscular Dystrophy Drug Sales by Countries
      • 9.1.2 Central & South America Becker Muscular Dystrophy Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Becker Muscular Dystrophy Drug by Product
    • 9.3 Central & South America Becker Muscular Dystrophy Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Becker Muscular Dystrophy Drug by Countries
      • 10.1.1 Middle East and Africa Becker Muscular Dystrophy Drug Sales by Countries
      • 10.1.2 Middle East and Africa Becker Muscular Dystrophy Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Becker Muscular Dystrophy Drug by Product
    • 10.3 Middle East and Africa Becker Muscular Dystrophy Drug by End User

    11 Company Profiles

    • 11.1 Italfarmaco SpA
      • 11.1.1 Italfarmaco SpA Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Italfarmaco SpA Becker Muscular Dystrophy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Italfarmaco SpA Becker Muscular Dystrophy Drug Products Offered
      • 11.1.5 Italfarmaco SpA Recent Development
    • 11.2 Milo Biotechnology LLC
      • 11.2.1 Milo Biotechnology LLC Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Milo Biotechnology LLC Becker Muscular Dystrophy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Milo Biotechnology LLC Becker Muscular Dystrophy Drug Products Offered
      • 11.2.5 Milo Biotechnology LLC Recent Development
    • 11.3 PTC Therapeutics Inc
      • 11.3.1 PTC Therapeutics Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 PTC Therapeutics Inc Becker Muscular Dystrophy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 PTC Therapeutics Inc Becker Muscular Dystrophy Drug Products Offered
      • 11.3.5 PTC Therapeutics Inc Recent Development
    • 11.4 ReveraGen BioPharma Inc
      • 11.4.1 ReveraGen BioPharma Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 ReveraGen BioPharma Inc Becker Muscular Dystrophy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 ReveraGen BioPharma Inc Becker Muscular Dystrophy Drug Products Offered
      • 11.4.5 ReveraGen BioPharma Inc Recent Development
    • 11.5 Sarepta Therapeutics Inc
      • 11.5.1 Sarepta Therapeutics Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Sarepta Therapeutics Inc Becker Muscular Dystrophy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Sarepta Therapeutics Inc Becker Muscular Dystrophy Drug Products Offered
      • 11.5.5 Sarepta Therapeutics Inc Recent Development

    12 Future Forecast

    • 12.1 Becker Muscular Dystrophy Drug Market Forecast by Regions
      • 12.1.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Becker Muscular Dystrophy Drug Market Forecast by Product
      • 12.2.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Product 2019-2025
    • 12.3 Becker Muscular Dystrophy Drug Market Forecast by End User
    • 12.4 North America Becker Muscular Dystrophy Drug Forecast
    • 12.5 Europe Becker Muscular Dystrophy Drug Forecast
    • 12.6 Asia Pacific Becker Muscular Dystrophy Drug Forecast
    • 12.7 Central & South America Becker Muscular Dystrophy Drug Forecast
    • 12.8 Middle East and Africa Becker Muscular Dystrophy Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Becker Muscular Dystrophy Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Becker Muscular Dystrophy Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Becker Muscular Dystrophy Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Becker Muscular Dystrophy Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Becker Muscular Dystrophy Drug in these regions.
      This research report categorizes the global Becker Muscular Dystrophy Drug market by top players/brands, region, type and end user. This report also studies the global Becker Muscular Dystrophy Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Italfarmaco SpA
      Milo Biotechnology LLC
      PTC Therapeutics Inc
      ReveraGen BioPharma Inc
      Sarepta Therapeutics Inc

      Market size by Product
      Givinostat
      Ataluren
      Epicatechin
      ARM-210
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Becker Muscular Dystrophy Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Becker Muscular Dystrophy Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Becker Muscular Dystrophy Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Becker Muscular Dystrophy Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Becker Muscular Dystrophy Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Becker Muscular Dystrophy Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now